{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:02:40Z","timestamp":1792047760954,"version":"4.4.0"},"reference-count":134,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Reports"],"abstract":"<jats:p>Over the past decade, the management of childhood acute lymphoblastic leukemia (ALL) has undergone remarkable advancements. This review explores the transition from conventional chemotherapy protocols to precision medicine approaches, highlighting improvements in diagnostic techniques, therapeutic strategies, and personalized treatments within front-line protocols. Key developments include enhanced minimal residual disease detection, the advent of immunotherapies, targeted therapies, and the integration of artificial intelligence. Despite these advancements, challenges remain in ensuring global access and equity. This article discusses the current state of ALL treatment and anticipates future directions in the field.<\/jats:p>","DOI":"10.3390\/pediatric17050108","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T07:29:38Z","timestamp":1760599778000},"page":"108","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Decade of Transformation in the Management of Childhood Acute Lymphoblastic Leukemia: From Conventional Chemotherapy to Precision Medicine"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-6671","authenticated-orcid":false,"given":"Maurizio","family":"Aric\u00f2","sequence":"first","affiliation":[{"name":"Pediatrics, Ospedale S. Spirito, Azienda Sanitaria Locale, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5697-4929","authenticated-orcid":false,"given":"Valentino","family":"Conter","sequence":"additional","affiliation":[{"name":"Centro Tettamanti, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(17)30186-9","article-title":"International incidence of childhood cancer, 2001\u201310: A population-based registry study","volume":"18","author":"Colombet","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: Progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S1470-2045(19)30031-2","article-title":"Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia","volume":"20","author":"Teachey","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1200\/JCO.2016.70.7836","article-title":"Genetic basis of acute lymphoblastic leukemia","volume":"35","author":"Iacobucci","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_6","first-page":"278","article-title":"A revised definition for cure of childhood acute lymphoblastic leukemia","volume":"35","author":"Pui","year":"2021","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1200\/JCO.23.01388","article-title":"Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study","volume":"42","author":"Conter","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet"},{"key":"ref_10","first-page":"415","article-title":"Genomics in acute lymphoblastic leukaemia: Insights and treatment implications","volume":"17","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood-2015-09-670729","article-title":"Dexamethasone vs prednisone in induction treatment of pediatric ALL: Results of the randomized trial AIEOP-BFM ALL 2000","volume":"127","author":"Zimmermann","year":"2016","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the children\u2019s oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1200\/JCO.2012.47.0500","article-title":"Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia","volume":"31","author":"Schmiegelow","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: A Delphi consensus","volume":"17","author":"Schmiegelow","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic Health Conditions in Adult Survivors of Childhood Cancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_16","first-page":"59","article-title":"Late Adverse Effects after Treatment for Childhood Acute Leukemia","volume":"53","author":"Roganovic","year":"2024","journal-title":"Acta Med. Acad."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1182\/blood-2007-10-117150","article-title":"Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study","volume":"111","author":"Mody","year":"2008","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1016\/S2352-3026(19)30050-X","article-title":"The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: A retrospective analysis of the St Jude Lifetime Cohort Study","volume":"6","author":"Mulrooney","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 protocol: Results from an international phase III randomized study","volume":"37","author":"Pieters","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41375-021-01460-6","article-title":"Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: Report from Children\u2019s Oncology Group Study AALL0232","volume":"36","author":"Burke","year":"2022","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3324\/haematol.2015.141101","article-title":"New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia","volume":"101","author":"Moorman","year":"2016","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(12)70580-6","article-title":"Relapsed childhood acute lymphoblastic leukaemia","volume":"14","author":"Bhojwani","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/leu.2009.268","article-title":"Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18\u201320 September 2008","volume":"24","author":"Schrauder","year":"2010","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1200\/JCO.2008.20.8934","article-title":"Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow","volume":"27","author":"Basso","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children\u2019s Oncology Group study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: Results of the AIEOP-BFM-ALL 2000 study","volume":"118","author":"Schrappe","year":"2011","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2017.74.4946","article-title":"Reduced-intensity delayed intensification in standard-risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: Results of an international randomized trial (AIEOP-BFM ALL 2000)","volume":"36","author":"Schrappe","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e14483","DOI":"10.1111\/petr.14483","article-title":"Transferring measurable residual disease measurement in pediatric acute lymphoblastic leukemia from quantitative real-time PCR to digital droplet PCR","volume":"27","author":"Luib","year":"2023","journal-title":"Pediatr. Transplant."},{"key":"ref_30","unstructured":"Della Starza, I., Chiaretti, S., De Propris, M.S., Elia, L., Cavalli, M., De Novi, L.A., Soscia, R., Messina, M., Vitale, A., and Guarini, A. (2021). Digital-droplet PCR for precise quantification of minimal residual disease in acute lymphoblastic leukemia. Front. Mol. Biosci., 8."},{"key":"ref_31","first-page":"327","article-title":"Analysis of signaling networks at the single-cell level using mass cytometry: Focus on acute myeloid leukemia","volume":"1636","author":"Bandyopadhyay","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","article-title":"Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL","volume":"131","author":"Wood","year":"2018","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.leukres.2018.10.009","article-title":"Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selection","volume":"76","author":"Theunissen","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood.2022017003","article-title":"NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol","volume":"141","author":"Svaton","year":"2023","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3324\/haematol.2017.186320","article-title":"Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion","volume":"104","author":"Ohki","year":"2019","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3324\/haematol.2016.151035","article-title":"ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype","volume":"102","author":"Shinsuke","year":"2017","journal-title":"Haematologica"},{"key":"ref_37","first-page":"123","article-title":"Transcriptome sequencing in pediatric acute lymphoblastic leukemia identifies fusion genes including MEF2D and ZNF384","volume":"10","author":"Dahlberg","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood.2022016241","article-title":"Functional, structural, and molecular characterizations of the leukemogenic driver MEF2D-HNRNPUL1 fusion","volume":"140","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"ref_39","first-page":"4","article-title":"Multimodal classification of molecular subtypes in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"3","author":"Krali","year":"2023","journal-title":"Nat. Prec. Oncol."},{"key":"ref_40","first-page":"456","article-title":"RNA-sequencing: A reliable tool to unveil transcriptional landscape of paediatric B-other acute lymphoblastic leukaemia","volume":"17","author":"Montesdeoca","year":"2025","journal-title":"Cancers"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100741","DOI":"10.1016\/j.modpat.2025.100741","article-title":"Molecular profiling reveals novel gene fusions and genetic markers for refined patient stratification in pediatric acute lymphoblastic leukemia","volume":"38","author":"Egyed","year":"2025","journal-title":"Mod. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study","volume":"39","author":"Peters","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_43","first-page":"207","article-title":"Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation for Children with ALL","volume":"24","author":"Leonard","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jtct.2021.01.016","article-title":"Outcomes of Unmanipulated Haploidentical Transplantation Using Post-Transplant Cyclophosphamide (PT-Cy) in Pediatric Patients with Acute Lymphoblastic Leukemia","volume":"27","author":"Ruggeri","year":"2021","journal-title":"Transpl. Cell Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.21037\/cco-23-115","article-title":"Radiation-free conditioning in acute lymphoblastic leukemia: Is it time?","volume":"13","author":"Mohty","year":"2024","journal-title":"Chin. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41408-023-00837-3","article-title":"Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL","volume":"13","author":"Qiu","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e33937","DOI":"10.1016\/j.heliyon.2024.e33937","article-title":"CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory\/relapsed B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-020-00342-x","article-title":"Blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia: Results of the RIALTO trial, an expanded access study","volume":"10","author":"Locatelli","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: A randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children with High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1200\/JCO.22.02200","article-title":"Children\u2019s Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults with Low-Risk B-Cell ALL in First Relapse","volume":"41","author":"Hogan","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children","volume":"392","author":"Gupta","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1002\/cncr.31720","article-title":"Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage","volume":"124","author":"Jabbour","year":"2018","journal-title":"Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","article-title":"Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"33","author":"Bhojwani","year":"2019","journal-title":"Leukemia"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","article-title":"Management of important adverse events associated with inotuzumab ozogamicin: Expert panel review","volume":"53","author":"Kebriaei","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.3324\/haematol.2023.284409","article-title":"Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: Results of the phase IB ITCC-059 trial","volume":"109","author":"Pennesi","year":"2024","journal-title":"Haematologica"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA approval summary: Tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"25","author":"Lu","year":"2019","journal-title":"Clin Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_64","first-page":"1411","article-title":"Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"138","author":"Grupp","year":"2021","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_67","first-page":"2","article-title":"Adult Survivorship: Considerations following CAR T-cell therapy","volume":"23","author":"Buitrago","year":"2019","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_68","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.1182\/blood-2024-201125","article-title":"Efficacy and Safety of Inaticabtagene Autoleucel in Children with Relapsed\/Refractory (R\/R) B-cell Acute Lymphoblastic Leukemia in China","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41591-024-03458-w","article-title":"T cell malignancies after CAR T\u2009cell therapy in the DESCAR-T registry","volume":"31","author":"Dulery","year":"2025","journal-title":"Nat. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1182\/bloodadvances.2022008093","article-title":"Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy","volume":"6","author":"Hsieh","year":"2022","journal-title":"Blood Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","article-title":"CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression","volume":"35","author":"Fousek","year":"2021","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","article-title":"Dual Targeting CAR-T Cells with Optimal Costimulation and Metabolic Fitness enhance Antitumor Activity and Prevent Escape in Solid Tumors","volume":"2","author":"Hirabayashi","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: The fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: Results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","article-title":"PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia","volume":"51","author":"Gu","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","article-title":"The genomic landscape of pediatric acute lymphoblastic leukemia","volume":"54","author":"Brady","year":"2022","journal-title":"Nat. Genet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/s41586-024-07807-0","article-title":"The genomic basis of childhood T-lineage acute lymphoblastic leukaemia","volume":"632","author":"Seffernick","year":"2024","journal-title":"Nature"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJM200004063421402","article-title":"Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"342","author":"Valsecchi","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: Children\u2019s Oncology Group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(12)70377-7","article-title":"Imatinib after induction for treatment of children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL): A randomised, open-label, intergroup study","volume":"13","author":"Biondi","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/S2352-3026(18)30173-X","article-title":"Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): A prospective, intergroup, open-label, single-arm clinical trial","volume":"5","author":"Biondi","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","article-title":"Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children\u2019s Oncology Group Trial AALL0622","volume":"36","author":"Slayton","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(23)00088-1","article-title":"Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372\/COG AALL1122): A single-arm, multicentre, phase 2 trial","volume":"10","author":"Hunger","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jamaoncol.2019.5868","article-title":"Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"6","author":"Shen","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"JAMA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/1078-0432.CCR-19-0090","article-title":"Pharmacokinetics of Nilotinib in Pediatric Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia","volume":"26","author":"Hijiya","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High frequency and poor outcome of Philadelphia chromosome\u2013like acute lymphoblastic leukemia in adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2016-12-758979","article-title":"Targetable kinase gene fusions in high-risk B-ALL: A study from the Children\u2019s Oncology Group","volume":"129","author":"Reshmi","year":"2017","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood-2011-12-389932","article-title":"Aberrant STAT5 and PI3K\/mTOR pathway activation in high-risk childhood acute lymphoblastic leukemia","volume":"120","author":"Tasian","year":"2012","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood.2023023153","article-title":"How I treat Philadelphia chromosome-like acute lymphoblastic leukemia in children, adolescents, and young adults","volume":"145","author":"Tran","year":"2025","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.1182\/blood-2022-164699","article-title":"A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521\/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations","volume":"140","author":"Tasian","year":"2022","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2352-3026(20)30353-7","article-title":"Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: A multicentre, retrospective, cohort study","volume":"8","author":"Cario","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"G\u00f3recki, M., Kozio\u0142, I., Kopystecka, A., Budzy\u0144ska, J., Zawitkowska, J., and Lejman, M. (2023). Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030821"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/leu.2017.279","article-title":"Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol","volume":"31","author":"Driessen","year":"2017","journal-title":"Leukemia"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia","volume":"388","author":"Kotecha","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","article-title":"Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia","volume":"128","author":"Khaw","year":"2016","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e31630","DOI":"10.1002\/pbc.31630","article-title":"Venetoclax Combined with Chemotherapy in Pediatric and Adolescent\/Young Adult Patients with Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"72","author":"Place","year":"2025","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-1998","article-title":"A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study","volume":"22","author":"Cooper","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_101","unstructured":"U.S. Food & Drug Administration (2025, September 05). FDA Approves Revumenib for Relapsed or Refractory Acute Leukemia with a KMT2A Translocation (Revuforj). 15 November 2024, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation?utm_source=chatgpt.com."},{"key":"ref_102","first-page":"3247","article-title":"Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options","volume":"117","author":"Stumpel","year":"2011","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Lygizou, E.M., Reiter, M., Maurer-Granofszky, M., Dworzak, M., and Grosu, R. (2024, January 15\u201319). Automated Immunophenotyping Assessment for Diagnosing Childhood Acute Leukemia using Set-Transformers. Proceedings of the 2024 46th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) 2024, Orlando, FL, USA.","DOI":"10.1109\/EMBC53108.2024.10781595"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1182\/bloodadvances.2021005894","article-title":"ALLSorts: An RNA-Seq subtype classifier for B-cell acute lymphoblastic leukemia","volume":"6","author":"Schmidt","year":"2020","journal-title":"Blood Adv."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s42256-019-0101-9","article-title":"Human-level recognition of blast cells in acute myeloid leukemia with convolutional neural networks","volume":"1","author":"Matek","year":"2019","journal-title":"Nat. Mach. Intell."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Pan, L., Liu, G., Lin, F., Zhong, S., Xia, H., Sun, X., and Liang, H. (2017). Machine learning applications for prediction of relapse in childhood acute lymphoblastic leukemia. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-07408-0"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"100654","DOI":"10.1016\/j.crmeth.2023.100654","article-title":"Clinical forecasting of acute myeloid leukemia using ex vivo drug-sensitivity profiling","volume":"3","author":"Andersen","year":"2023","journal-title":"Cell Rep. Methods"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nmeth.2365","article-title":"Critical assessment of automated flow cytometry data analysis techniques","volume":"10","author":"Aghaeepour","year":"2013","journal-title":"Nat. Methods"},{"key":"ref_109","first-page":"344","article-title":"Pharmacogenetics and personalized medicine in ALL","volume":"12","author":"Relling","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/ng.763","article-title":"Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia","volume":"43","author":"Yang","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/ng.3508","article-title":"NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity","volume":"48","author":"Moriyama","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"100222","DOI":"10.1016\/j.ejcped.2025.100222","article-title":"Curing using the minimal\u2014Strategies for treatment reduction in childhood acute lymphoblastic leukemia","volume":"5","author":"Oh","year":"2025","journal-title":"EJC Paediatr. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41467-022-29224-5","article-title":"Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines","volume":"13","author":"Leo","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_114","first-page":"219","article-title":"Treating childhood cancer in low- and middle-income countries","volume":"15","author":"Gupta","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1126\/science.aaw4892","article-title":"Science and health for all children with cancer","volume":"363","author":"Lam","year":"2019","journal-title":"Science"},{"key":"ref_116","first-page":"e189","article-title":"Strategies to improve care for children with cancer in sub-Saharan Africa","volume":"14","author":"Israels","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/pbc.24911","article-title":"Treatment of childhood acute lymphoblastic leukemia in central America: A lower-middle income countries experience","volume":"61","author":"Navarrete","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Witek, M.A., Larkey, N.E., Bartakova, A., Hupert, M.L., Mog, S., Cronin, J.K., Vun, J., August, K.J., and Soper, S.A. (2024). Microfluidic Affinity Selection of B-Lineage Cells from Peripheral Blood for Minimal Residual Disease Monitoring in Pediatric B-Type Acute Lymphoblastic Leukemia Patients. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251910619"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S1470-2045(20)30022-X","article-title":"Sustainable care for children with cancer: A Lancet Oncology Commission","volume":"21","author":"Atun","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(98)07077-9","article-title":"North-South twinning in paediatric haemato-oncology: The La Mascota programme, Nicaragua","volume":"352","author":"Masera","year":"1998","journal-title":"Lancet"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.2014.60.6376","article-title":"Toward the Cure of All Children with Cancer Through Collaborative Efforts: Pediatric Oncology as a Global Challenge","volume":"33","author":"Friedrich","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e2300256","DOI":"10.1200\/GO.23.00256","article-title":"Unification of Efforts to Improve Global Access to Cancer Therapeutics: Report From the 2022\/2023 Access to Essential Cancer Medicines Stakeholder Summit","volume":"10","author":"Briercheck","year":"2024","journal-title":"JCO Glob. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e000571","DOI":"10.1136\/bmjgh-2017-000571","article-title":"Estimated costs of production and potential prices for the WHO essential medicines list","volume":"3","author":"Hill","year":"2018","journal-title":"BMJ Glob. Health"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/JCO.2013.49.1845","article-title":"Cancer drugs in the United States: Justum pretium\u2014The just price","volume":"31","author":"Kantarjian","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1200\/JGO.2015.000570","article-title":"Novel Humanitarian Aid Program: The Glivec International Patient Assistance Program\u2014Lessons Learned from Providing Access to Breakthrough Targeted Oncology Treatment in Low- and Middle-Income Countries","volume":"1","author":"Boultbee","year":"2015","journal-title":"J. Glob. Oncol."},{"key":"ref_126","unstructured":"World Health Organization, St. Jude Children\u2019s Research Hospital, UNICEF, and Pan American Health Organization (PAHO) (2025, September 05). Global Platform for Access to Childhood Cancer Medicines. Available online: https:\/\/www.who.int\/teams\/noncommunicable-diseases\/ncds-management\/cancer-programme\/global-platform-for-access-to-childhood-cancer-medicines."},{"key":"ref_127","unstructured":"ACT for Children (2025, September 05). Access to Childhood Cancer Treatment in LMICs. Available online: https:\/\/act-4-children.org\/."},{"key":"ref_128","unstructured":"International Society of Paediatric Oncology (SIOP) (2025, September 05). Tackling Inequities in Childhood Cancer Through Unique Global Collaboration. News Release; 12 February 2025. Available online: https:\/\/siop-online.org\/news\/tackling-inequities-in-childhood-cancer-through-unique-global-collaboration\/."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1001\/jama.2013.6296","article-title":"Clinical ascertainment of health outcomes among adults treated for childhood cancer","volume":"309","author":"Hudson","year":"2013","journal-title":"JAMA"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pcl.2014.09.004","article-title":"Biology of childhood acute lymphoblastic leukemia","volume":"62","author":"Bhojwani","year":"2015","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_131","unstructured":"Wolters Kluwer (2025, September 22). Chimeric Antigen Receptor (CAR) T Cell Therapy: A Remarkable Breakthrough in Cancer Treatment. Expert Insights. 21 August 2023. Available online: https:\/\/www.wolterskluwer.com\/en\/expert-insights\/car-t-cell-therapy-a-remarkable-breakthrough-in-cancer-treatment."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014Assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Kantarjian, H., Pui, C.H., and Jabbour, E. (2025). Acute lymphocytic leukaemia. Lancet, Epub ahead of print.","DOI":"10.1016\/S0140-6736(25)00864-5"}],"container-title":["Pediatric Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2036-7503\/17\/5\/108\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:20:16Z","timestamp":1760602816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7503\/17\/5\/108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":134,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["pediatric17050108"],"URL":"https:\/\/doi.org\/10.3390\/pediatric17050108","relation":{},"ISSN":["2036-7503"],"issn-type":[{"value":"2036-7503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]}}}